Publications by authors named "Maria Isabel Fleischer"

Claim this Profile
F
First-line checkpoint inhibitor therapy in metastatic acral lentiginous melanoma compared to other types of cutaneous melanoma: A multicenter study from the prospective skin cancer registry ADOREG.
Sören Reinhard, Jochen Sven Utikal, Anne Zaremba, Georg Lodde, Imke von Wasielewski, Maria Isabel Fleischer

Eur J Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protease- and cell type-specific activation of protease-activated receptor 2 in cutaneous inflammation.
Maria Isabel Fleischer, Nadine Röhrig, Verena K Raker, Juliane Springer, Detlef Becker

J Thromb Haemost· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma-A Retrospective, Real-World Cohort Study.
Maximilian Haist, Henner Stege, Ronja Ebner, Maria Isabel Fleischer, Carmen Loquai

Cancers (Basel)· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anticoagulation with Factor Xa Inhibitors Is Associated with Improved Overall Response and Progression-Free Survival in Patients with Metastatic Malignant Melanoma Receiving Immune Checkpoint Inhibitors-A Retrospective, Real-World Cohort Study.
Maximilian Haist, Henner Stege, Saskia Pemler, Jaqueline Heinz, Maria Isabel Fleischer

Cancers (Basel)· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology Centers.
Christian D Sadik, Ewan A Langan, Ralf Gutzmer, Maria Isabel Fleischer, Carmen Loquai

Front Immunol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma-A Retrospective Multicenter ADOReg Study.
Henner Stege, Maximilian Haist, Michael Schultheis, Maria Isabel Fleischer, Peter Mohr

Cancers (Basel)· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis